Loading clinical trials...
Loading clinical trials...
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
Conditions
Interventions
IDP-023
Ocrelizumab
+4 more
Locations
5
United States
Stanford University
Stanford, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
AdventHealth Orlando - Adventist Health System/Sunbelt, Inc.
Orlando, Florida, United States
Kansas University Medical Center
Kansas City, Kansas, United States
Washington University in St. Louis
St Louis, Missouri, United States
Start Date
June 30, 2026
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2028
Last Updated
April 30, 2025
NCT07325292
NCT05748015
NCT06433765
NCT04876339
NCT07466823
NCT05344469
Lead Sponsor
Indapta Therapeutics, INC.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions